Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting No phase listed Observational

An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms

ClinicalTrials.gov ID: NCT07490431

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07490431. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RELIEF: Real-world Evidence on eLInzanEtant For the Treatment of Hot Flashes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life harder. Elinzanetant is a new, hormone free medicine that works by blocking certain signal ways in the brain that are linked to these symptoms. It has already been shown in clinical studies to help reduce hot flashes. This study is being done to learn about how elinzanetant is used, how well it works, and how safe it is for women with menopause symptoms in real-world, everyday medical care. The main goal is to understand who is starting treatment with elinzanetant and what symptoms they have. The study will also look at how well elinzanetant helps with hot flashes, night sweats, and sleep problems, how safe it is, how satisfied women are with the treatment, and how it affects their quality of life and daily activities. To do this, researchers will follow about 1,500 women in the United States who are starting elinzanetant as part of their usual care. Women will answer questions about their symptoms, sleep, and daily life using a secure app on their phone or computer. Some women will also wear a smart ring for a few weeks to collect information about their sleep. The study will last about 12 weeks for most women, but some will be followed for up to 2 years. No extra treatments or tests will be given as part of the study-researchers will only collect information about how women are doing while taking elinzanetant as prescribed by their own doctor. The results will help doctors and patients understand how elinzanetant works in real life and support better care for women going through menopause.

Study identification

NCT ID
NCT07490431
Recruitment status
Not yet recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Bayer
Industry
Enrollment
2,400 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2026 (Estimated)
Primary completion
Nov 30, 2029 (Estimated)
Completion
Nov 30, 2029 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2029

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
AMR Clinical-Mobile Mobile Alabama 36608 —
Applied Research Center of Arkansas Little Rock Arkansas 72205 —
University of Colorado Anschutz Denver Colorado 80045 —
Yale School of Medicine New Haven Connecticut 06510 —
AMR Clinical Fort Myers Fort Myers Florida 33912 —
Southside Women's Health Specialists-Emerson Jacksonville Florida 32207 —
Entrust Clinical Research Kendall Florida 33176 —
Eminat, LLC Miramar Florida 33027 —
Renew Health Clinical Research LLC Snellville Georgia 30078 —
Next Innovative Clinical Research Chicago Illinois 60616 —
Tufts Medical Center Boston Massachusetts 02111 —
Maimonides Medical Center Brooklyn New York 11219 —
Atrium Health Charlotte North Carolina 28211 —
Duke Health Raleigh North Carolina 27587 —
University Hospitals Landerbrook Health Center Mayfield Heights Ohio 44124 —
Haven Center Tulsa Oklahoma 74137 —
MUSC Charleston South Carolina 29425 —
UT Health Women's Research Program-Memorial City Houston Texas 77024 —
Maximos Ob/Gyn League City Texas 77573 —
Focus Clinical Research Solutions Reston Virginia 20190 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07490431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.